Aptamer‐siRNA chimeras: Promising tools for targeting HER2 signaling in cancer

Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

(2022) Maher M. Aljohani et al.   MOLECULES

Drug delivery systems for RNA therapeutics

(2022) Kalina Paunovska et al.   NATURE REVIEWS GENETICS

Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2 + Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis

(2022) Worapol Ngamcherdtrakul et al.   Small

Translation of aptamers toward clinical diagnosis and commercialization

(2022) Shan Liu et al.   BIOSENSORS & BIOELECTRONICS

Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma

(2021) Dexuan Xiao et al.   ACS Applied Materials & Interfaces

Lumasiran: First Approval

(2021) Lesley J. Scott et al.   DRUGS

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer

(2021) Sandeep Pallerla et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer

(2021) Sreeram V. Ramagopalan et al.   JAMA Network Open

Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer

(2021) Jialang Zhuang et al.   International Journal of Nanomedicine

Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy

(2021) Yuming Yang et al.   JOURNAL OF NANOBIOTECHNOLOGY

Aptamer-based diagnostic and therapeutic approaches in animals: Current potential and challenges

(2021) Sapna Devi et al.   SAUDI JOURNAL OF BIOLOGICAL SCIENCES

Insight Into the Prospects for RNAi Therapy of Cancer

(2021) Zhili Tian et al.   Frontiers in Pharmacology

Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX

(2021) Frank H. T. Nelissen et al.   Pharmaceuticals

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

(2021) Ilana Schlam et al.   npj Breast Cancer

HER2 as a predictive biomarker and treatment target in colorectal cancer

(2020) Astrid De Cuyper et al.   Clinical Colorectal Cancer

Givosiran: First Approval

(2020) Lesley J. Scott   DRUGS

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual Targeted Therapy in HER2-positive Breast Cancer Cells with the Combination of Carbon Dots/HER3 siRNA and Trastuzumab

(2020) Mengjun Shu et al.   NANOTECHNOLOGY

Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

(2020) María Florencia Mercogliano et al.   Frontiers in Oncology

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

(2020) Qitong Chen et al.   Frontiers in Oncology

Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment

(2020) Nusrat Chowdhury et al.   AAPS PHARMSCITECH

Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer

(2020) Long Zhang et al.   ACS Applied Materials & Interfaces

Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells

(2020) Arif Khan et al.   International Journal of Nanomedicine

Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation

(2020) Marco Gaviraghi et al.   Scientific Reports

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy

(2020) Hwa Yeon Jeong et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

EpCAM-Targeted 3WJ RNA Nanoparticle Harboring Delta-5-Desaturase siRNA Inhibited Lung Tumor Formation via DGLA Peroxidation

(2020) Lizhi Pang et al.   Molecular Therapy-Nucleic Acids

HER-2 Aptamer Targeted Ecoflex® Nanoparticles Loaded With Docetaxel Promote Breast Cancer Cells Apoptosis and Anti-Metastatic Effect

(2019) Jaleh Varshosaz et al.   IET Nanobiotechnology

Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2+ breast cancer

(2019) Zhuang Tang et al.   JOURNAL OF DRUG TARGETING

Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells

(2019) Tayebeh Saleh et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency

(2019) J. Bruniaux et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editorial focus: understanding off-target effects as the key to successful RNAi therapy

(2019) Rafal Bartoszewski et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)

(2019) Zhuyu Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells

(2019) Barbara Dapas et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

EGFRvIII: An Oncogene with Ambiguous Role

(2019) Adrianna Rutkowska et al.   Journal of Oncology

Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells

(2019) Tatiane Cristofolini et al.   Materials Science & Engineering C-Materials for Biological Applications

Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells

(2018) Shabanali Khodashenas Limoni et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

RNA Therapeutics in Cardiovascular Disease

(2018) Tina Lucas et al.   CIRCULATION RESEARCH

Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

(2018) Xiao-qian Dou et al.   International Journal of Nanomedicine

Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents

(2018) Minhee Kim et al.   MOLECULES

The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies

(2018) Hui Luo et al.   PLoS One

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment

(2018) Shenda Gu et al.   PLoS One

Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer

(2018) Bethany Powell Gray et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice

(2018) Wataru Shibata et al.   Scientific Reports

STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma

(2018) Carla Lucia Esposito et al.   Molecular Therapy-Nucleic Acids

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2 + Breast Cancer

(2018) Xiaolin Yu et al.   Molecular Therapy-Nucleic Acids

Patisiran: First Global Approval

(2018) Sheridan M. Hoy   DRUGS

Synergistic targeting HER2 and EGFR with a bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth

(2018) LU XUE et al.   MOLECULAR PHARMACEUTICS

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo

(2018) Xiaoli Wang et al.   Drug Design Development and Therapy

Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression

(2018) Yi Xu et al.   Redox Biology

An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma

(2018) Sorah Yoon et al.   Molecular Therapy-Nucleic Acids

Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer

(2017) David Powell et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Characterization of aptamer-mediated gene delivery system for liver cancer therapy

(2017) Zhongbing Liu et al.   Oncotarget

Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles

(2016) Yijuan Zhang et al.   ACS Nano

Aptamers as targeted therapeutics: current potential and challenges

(2016) Jiehua Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine

(2016) Cheng Wang et al.   Oncotarget

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth

(2016) Yuan Lu et al.   Oncotarget

Therapeutic siRNA for drug-resistant HER2-positive breast cancer

(2016) Shenda Gu et al.   Oncotarget

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells

(2016) Maria C. Palanca-Wessels et al.   Oncotarget

A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects

(2016) Wei-Yun Lai et al.   Molecular Therapy-Nucleic Acids

HER2 RNA Aptamer- and Cell Penetrating Peptide-Mediated Delivery of Multimeric Antisense Strands of siRNAs for Gene Silencing

(2016) Sungmuk Kang et al.   BULLETIN OF THE KOREAN CHEMICAL SOCIETY

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+Breast Cancer

(2015) Worapol Ngamcherdtrakul et al.   ADVANCED FUNCTIONAL MATERIALS

Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy

(2015) Kuo Jiang et al.   BIOMATERIALS

Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy

(2015) Lukas J Aaldering et al.   RNA Biology

Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras

(2015) Nithya Subramanian et al.   Nucleic Acid Therapeutics

Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA)

(2015) Behzad Mansoori et al.   Artificial Cells Nanomedicine and Biotechnology

Role of ErbB Receptors in Cancer Cell Migration and Invasion

(2015) Aline Appert-Collin et al.   Frontiers in Pharmacology

siRNA Versus miRNA as Therapeutics for Gene Silencing

(2015) Jenny K W Lam et al.   Molecular Therapy-Nucleic Acids

Delivery systems for siRNA drug development in cancer therapy

(2015) Cong-fei Xu et al.   Asian Journal of Pharmaceutical Sciences

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

(2014) N. Elster et al.   BREAST CANCER RESEARCH AND TREATMENT

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells

(2014) Andreas Herrmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFRβ Aptamer

(2014) Simona Camorani et al.   MOLECULAR THERAPY

ScFv-Decorated PEG-PLA-Based Nanoparticles for Enhanced siRNA Delivery to Her2+Breast Cancer

(2014) Shuang Dou et al.   Advanced Healthcare Materials

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

(2013) Baris Boyraz et al.   CURRENT MEDICAL RESEARCH AND OPINION

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

Site-Specific Antibody–Polymer Conjugates for siRNA Delivery

(2013) Hua Lu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes

(2013) Yuya Nishimura et al.   JOURNAL OF NANOBIOTECHNOLOGY

Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers

(2012) Kristina W. Thiel et al.   NUCLEIC ACIDS RESEARCH

Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX

(2011) Kazem Dastjerdi et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells

(2011) Mee Young Kim et al.   Nucleic Acid Therapeutics

Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer

(2010) Amye J. Tevaarwerk et al.   CLINICAL THERAPEUTICS

Aptamer applications for targeted cancer therapy

(2010) Andrew S Barbas et al.   Future Oncology

The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data

(2010) Lingxiang Liu et al.   Journal of Thoracic Oncology

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

(2009) Jie Gao et al.   BIOMATERIALS

Origins and Mechanisms of miRNAs and siRNAs

(2009) Richard W. Carthew et al.   CELL

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

(2009) Justin P Dassie et al.   NATURE BIOTECHNOLOGY

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways

(2007) Martín A. Rivas et al.   EXPERIMENTAL CELL RESEARCH